The Role of Regulator-Imposed Post-Approval Studies in Health Technology Assessments for Conditionally Approved Drugs
BackgroundThe European Medicines Agency (EMA) aims to resolve uncertainties associated with conditionally approved drugs by imposing post-approval studies. Results from these studies may be relevant for health technology assessment (HTA) organizations. This study investigated the role of regulator-i...
Main Authors: | Rick A. Vreman, Lourens T. Bloem, Stijn van Oirschot, Jarno Hoekman, Menno E. van der Elst, Hubert GM Leufkens, Olaf H. Klungel, Wim G. Goettsch, Aukje K. Mantel-Teeuwisse |
---|---|
Format: | Article |
Language: | English |
Published: |
Kerman University of Medical Sciences
2022-05-01
|
Series: | International Journal of Health Policy and Management |
Subjects: | |
Online Access: | https://www.ijhpm.com/article_3939_5237014b5da5bd1d788b68c53f91716a.pdf |
Similar Items
-
Associations between uncertainties identified by the European Medicines Agency and national decision making on reimbursement by HTA agencies
by: Lourens T. Bloem, et al.
Published: (2021-07-01) -
Fragility of randomized trials supporting cancer drug approvals stratified by approval pathway and review designations
by: Brooke E. Wilson, et al.
Published: (2021-08-01) -
Tools for assessing quality of studies investigating health interventions using real-world data: a literature review and content analysis
by: Aukje K Mantel-Teeuwisse, et al.
Published: (2024-02-01) -
Drugs approved by CDSCO, India in 2015
by: K Parushuram Naik1 , V Sai Lakshmi2 , J Jyothirmai3
Published: (2016-04-01) -
Evidence of pre-approval clinical trial supporting the granted conditional approval for novel cancer drugs in China between 2015 and 2022Research in context
by: Xingxian Luo, et al.
Published: (2023-09-01)